BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T, Kitabatake S, Kuzuya T, Nonogaki K, Kasugai T, Shimizu J. Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan. Cancer. 2004;100:2415-2421. [PMID: 15160346 DOI: 10.1002/cncr.20289] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen CH, Su WW, Yang SS, Chang TT, Cheng KS, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ. Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11,312 patients in Taiwan. J Gastroenterol Hepatol. 2006;21:1561-1566. [PMID: 16928217 DOI: 10.1111/j.1440-1746.2006.04425.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
2 Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019; 11(1): 50-64 [PMID: 30705718 DOI: 10.4254/wjh.v11.i1.50] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
3 Nguyen VT, Amin J, Law MG, Dore GJ. Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia. J Gastroenterol Hepatol. 2009;24:436-442. [PMID: 19175834 DOI: 10.1111/j.1440-1746.2008.05577.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
4 Hassanipour S, Vali M, Gaffari-Fam S, Nikbakht HA, Abdzadeh E, Joukar F, Pourshams A, Shafaghi A, Malakoutikhah M, Arab-Zozani M, Salehiniya H, Mansour-Ghanaei F. The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. EXCLI J 2020;19:108-30. [PMID: 32038120 DOI: 10.17179/excli2019-1842] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
5 Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 2005;100:1764-71. [PMID: 16086713 DOI: 10.1111/j.1572-0241.2005.41943.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 3.5] [Reference Citation Analysis]
6 Chen JG, Zhu J, Zhang YH, Chen YS, Ding LL, Chen HZ, Shen AG, Wang GR. Liver Cancer Survival: A Real World Observation of 45 Years with 32,556 Cases. J Hepatocell Carcinoma 2021;8:1023-34. [PMID: 34513745 DOI: 10.2147/JHC.S321346] [Reference Citation Analysis]
7 Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, Toyoda H, Nguyen MH. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology. 2020;71:1910-1922. [PMID: 31610027 DOI: 10.1002/hep.30988] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
8 Toyoda H, Kumada T, Sone Y. Impact of a unified CT angiography system on outcome of patients with hepatocellular carcinoma. AJR Am J Roentgenol. 2009;192:766-774. [PMID: 19234276 DOI: 10.2214/ajr.08.1368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
9 Chiappini F. Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol. 2012;2012:684802. [PMID: 22690340 DOI: 10.1155/2012/684802] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
10 Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, Satomura S. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein & lt; 20 ng/mL. Cancer Sci. 2011;102:1025-1031. [PMID: 21244578 DOI: 10.1111/j.1349-7006.2011.01875.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 5.7] [Reference Citation Analysis]
11 Jiang Z, Jiang X, Chen S, Lai Y, Wei X, Li B, Lin S, Wang S, Wu Q, Liang Q, Liu Q, Peng M, Yu F, Weng J, Du X, Pei D, Liu P, Yao Y, Xue P, Li P. Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. Front Immunol. 2016;7:690. [PMID: 28123387 DOI: 10.3389/fimmu.2016.00690] [Cited by in Crossref: 54] [Cited by in F6Publishing: 81] [Article Influence: 10.8] [Reference Citation Analysis]
12 Park KW, Park JW, Kim TH, Choi JI, Kim SH, Park HS, Park SJ, Lee WJ, Shin HL, Kim CM. [Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea]. Korean J Hepatol 2007;13:530-42. [PMID: 18159151 DOI: 10.3350/kjhep.2007.13.4.530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
13 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 17.7] [Reference Citation Analysis]
14 Jang HJ, Kim TK, Wilson SR. Small nodules (1-2 cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound. Eur J Radiol. 2009;72:418-424. [PMID: 18834687 DOI: 10.1016/j.ejrad.2008.08.011] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
15 Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y, Itoh A, Ishigami M, Hayashi K, Honda T. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:1929-1935. [PMID: 17914972 DOI: 10.1111/j.1440-1746.2006.04707.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
16 Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510. [PMID: 19141028 DOI: 10.1111/j.1478-3231.2008.01957.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 200] [Article Influence: 14.2] [Reference Citation Analysis]
17 Kim TK, Jang HJ, Wilson SR. Imaging diagnosis of hepatocellular carcinoma with differentiation from other pathology. Clin Liver Dis 2005;9:253-79. [PMID: 15831272 DOI: 10.1016/j.cld.2004.12.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
18 Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Characteristics and prognosis of patients with hepatocellular carcinoma after the year 2000 in Japan. J Gastroenterol Hepatol 2011;26:1765-71. [PMID: 21615793 DOI: 10.1111/j.1440-1746.2011.06789.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
19 Liao YP, Kung PT, Wang YH, Chu YR, Kao ST, Tsai WC. Effects and Relative Factors of Adjunctive Chinese Medicine Therapy on Survival of Hepatocellular Carcinoma Patients: A Retrospective Cohort Study in Taiwan. Integr Cancer Ther 2020;19:1534735420915275. [PMID: 32552053 DOI: 10.1177/1534735420915275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wang AG, Moon HB, Lee MR, Hwang CY, Kwon KS, Yu SL, Kim YS, Kim M, Kim JM, Kim SK. Gender-dependent hepatic alterations in H-ras12V transgenic mice. J Hepatol. 2005;43:836-844. [PMID: 16087271 DOI: 10.1016/j.jhep.2005.04.012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
21 Chinnaratha MA, Graham C, Fraser RJL, Woodman RJ, Wigg AJ. Rising incidence of hepatitis B-related hepatocellular carcinoma in South Australia: 1996-2010: Hepatitis B-related HCC in South Australia. Intern Med J 2016;46:902-8. [DOI: 10.1111/imj.13121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Lu Y, Hu J, Lin X, Li X. Bone metastases from hepatocellular carcinoma: clinical features and prognostic factors. Hepatobiliary & Pancreatic Diseases International 2017;16:499-505. [DOI: 10.1016/s1499-3872(16)60173-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
23 Goh GB, Li JW, Chang PE, Chow KY, Tan CK. Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades. Hepatol Commun 2017;1:564-71. [PMID: 29404479 DOI: 10.1002/hep4.1059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
24 Kim S, Choi Y, Kwak DW, Lee HS, Hur WJ, Baek YH, Lee SW. Prognostic factors in hepatocellular carcinoma patients with bone metastases. Radiat Oncol J 2019;37:207-14. [PMID: 31591869 DOI: 10.3857/roj.2019.00136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 He J, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, Wang JH, Sun J, Chen B, Yang P, Pan BS. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer. 2009;115:2710-2720. [PMID: 19382203 DOI: 10.1002/cncr.24300] [Cited by in Crossref: 83] [Cited by in F6Publishing: 69] [Article Influence: 6.4] [Reference Citation Analysis]
26 Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J. Characteristics and prognosis of patients in Japan with viral marker-negative hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:459-66. [PMID: 17854425 DOI: 10.1111/j.1440-1746.2007.05138.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
27 Toyoda H, Kumada T, Tada T, Mizuno K, Hiraoka A, Tsuji K, Ishikawa T, Akita T, Tanaka J. Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias. Liver Int 2018;38:2260-8. [PMID: 29981527 DOI: 10.1111/liv.13927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
28 Habermehl D, Haase K, Rieken S, Debus J, Combs SE. Defining the role of palliative radiotherapy in bone metastasis from primary liver cancer: An analysis of survival and treatment efficacy. Tumori 2011;97:609-13. [DOI: 10.1177/030089161109700512] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
29 Lee SS, Shin HS, Kim HJ, Lee SJ, Lee HS, Hyun KH, Kim YH, Kwon BW, Han JH, Choi H, Kim BH, Lee JH, Kang HY, Shin HD, Song IH. Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol 2012;18:48-55. [PMID: 22511903 DOI: 10.3350/kjhep.2012.18.1.48] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
30 Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, Matsunaga T. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol. 2006;4:1528-1536. [PMID: 17162244 DOI: 10.1016/j.cgh.2006.09.021] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
31 Danta M, Barnes E, Dusheiko G. The surveillance and diagnosis of hepatocellular carcinoma: . European Journal of Gastroenterology & Hepatology 2005;17:491-6. [DOI: 10.1097/00042737-200505000-00004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
32 Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol. 2015;29:919-928. [PMID: 26651253 DOI: 10.1016/j.bpg.2015.09.007] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 10.6] [Reference Citation Analysis]
33 Wang CY, Li S. Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma: A single center 14 years experience from China. Medicine (Baltimore) 2019;98:e14070. [PMID: 30681563 DOI: 10.1097/MD.0000000000014070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
34 Beaugrand M, Trinchet JC. [Non-surgical treatment of hepatocellular carcinoma. An overview]. Cancer Radiother 2005;9:464-9. [PMID: 16236541 DOI: 10.1016/j.canrad.2005.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]